



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 8/1/02

Signature: *Anna P. Lucey*
(Anna P. Lucey)

COPY OF PAPERS
ORIGINALLY FILED

Docket No.: CIBT-P02-540
(PATENT)

16557
#13/105

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Sampath et al.

Application No.: 09/613177

Filed: July 10, 2000

For: METHODS AND COMPOSITIONS FOR
IDENTIFYING MORPHOGEN ANALOGS

Group Art Unit: 1655

Examiner: Fredman, J.

RECEIVED

AUG 09 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 C.F.R. 1.17(p).

In accordance with 37 C.F.R. 1.98(d), applicants respectfully submit that no copy of any patent, publication, or other information listed on the enclosed Form PTO/SB/08 is needed because the citations were made in the prior parent application U.S.S.N. 08/764,522 filed December 12, 1996, which is relied upon for an earlier filing date under 35 U.S.C. 120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

08/08/2002 NMOHAMM1 00000158 181945 09613177

01 FC:126

180.00 CH

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Dated:

Respectfully submitted,

By  _____
Yu Lu

Registration No.: 50,306
ROPES & GRAY
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys for Applicant

COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/17 (11-01)

Approved for use through 10/31/2002. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2002

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180.00**Complete if Known**

Application Number	09/613177
Filing Date	July 10, 2000
First Named Inventor	Sampath et al.
Examiner Name	Fredman, J.
Group Art Unit	1655
Attorney Docket No.	CIBT-P02-540

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account

Deposit Account Number

18-1945

Deposit Account Name

Ropes & Gray

The Commissioner is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) during the pendency of this application☐ Charge fee(s) indicated below, except for the filing fee

to the above-identified deposit account.

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	180.00
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37CFR 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	
Other fee (specify)					
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3) (\$)					180.00

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	
SUBTOTAL (1) (\$)					0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		Extra Claims	Fee from below	Fee Paid
Independent Claims				
Multiple Dependent				

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
103	18	203	9	Claims in excess of 20	
102	84	202	42	Independent claims in excess of 3	
104	280	204	140	Multiple dependent claim, if not paid	
109	84	209	42	** Reissue independent claims over original patent	
110	18	210	9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$)

0.00

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY

Name (Print/Type) Yu Lu

Registration No. (Attorney/Agent)

50,306

Complete (if applicable)

Telephone (617) 951-7268

Signature

Date

AUG 09 2002

RECEIVED

Form PTO/SB/08

INFORMATION DISCLOSURE CITATION

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)

CIBT-P02-540

Application Number

09/613,177

Applicant

Sampath et al.

Filing Date

July 10, 2000

Group Art Unit

1655

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 5,578,708	11/26/96	Ozazaki et al.	RECEIVED AUG 09 2002		
	AB 5,665,543	9/9/97	Foulkes et al.			

TECH CENTER 1600-2900


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	AC	WO 93/05172	3/18/93	PCT				
	AD	WO 95/11983	5/4/95	PCT				
	AE	WO 95/14104	5/26/95	PCT				
	AF	WO 95/33831	12/14/95	PCT				
	AG	WO 96/08197	3/21/96	PCT				
	AH	WO 96/34101	10/31/96	PCT				
	AI	WO 96/34951	11/7/96	PCT				
	AJ	WO 96/38590	12/5/96	PCT				
	AK	WO 97/05285	2/13/97	PCT				
	AL	WO 97/05241	2/13/97	PCT				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

AM	Asahina et al. Human Osteogenic Protein-1 Induces Both Chondroblastic and Osteoblastic Differentiation of Osteoprogenitor Cells Derived from Newborn Rat Calvaria. <i>J. Cell Biol.</i> 123, 921-933 (1993).
AN	Asahina et al. Human Osteogenic Protein-1 Induces Chondroblastic, Osteoblastic, and/or Adipocytic Differentiation of Clonal Murine Target Cells. <i>Exp. Cell Res.</i> 222, 38-47 (1996).
AO	Bogdanovic et al. Upstream Regulatory Elements Necessary for Expression of the Rat COL1A1 Promoter in Transgenic Mice. <i>J. Bone & Min. Res.</i> 9, 285-292 (1994).
AP	Carcy et al. Expression of Bone Morphogenetic Protein-6 Messenger RNA in Bovine Growth Plate Chondrocytes of Different Size. <i>J. Bone & Min. Res.</i> 10, 401-405 (1995).
AQ	Chen et al. Bovine Articular Chondrocytes do not Undergo Hypertrophy when Cultured in the Presence of Serum and Osteogenic Protein-1. <i>Biochem. & Biophys. Res. Comm.</i> 197, 1253-1259 (1993).
AR	Chen et al. Osteogenic Protein-1 Promotes Growth and Maturation of Chick Sternal Chondrocytes in Serum-Free Cultures. <i>J. Cell Sci.</i> 108, 105-114 (1995).

Form PTO/SB/08		Docket Number (Optional)	Application Number
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		CIBT-P02-540	09/613,177
		Applicant	
		Sampath et al.	
		Filing Date	Group Art Unit
		July 10, 2000	1655
		Ducy et al. Two distinct osteoblast specific cis-acting elements control expression of a mouse osteocalcin gene. <i>Mol. Cell. Biol.</i> 15, 1858-1869 (1995).	
	AT	Elima et al. The Mouse Collagen X Gene: Complete Nucleotide Sequence, Exon Structure and Expression Pattern. <i>Biochem J.</i> 289, 247-253 (1993).	
	AU	Galera et al. C-Krox Binds to Several Sites in the Promoter of Both Mouse Type I Collagen Genes: Structure/Function Study and Development Expression Analysis. <i>J. Biol. Chem.</i> 271, 21331-21339 (1996).	
	AV	Galera et al. C-Krox a Transcriptional Regulator of Type I Collagen Gene Expression is Preferentially Expressed in Skin. <i>PNAS</i> 91, 9372-9376 (1994).	
	AW	Geoffroy et al. A PEBP2 alpha/AML-1-Related Factor Increases Osteocalcin Promoter Activity Through its Binding to an Osteoblast-Specific cis-Acting Element. <i>J. Biol. Chem.</i> 270, 30973-30979 (1995).	
	AX	Ghosh-Choudhury et al. Immortalized Murine Osteoblasts Derived from BMP 2-T-Antigen Expressing Transgenic Mice. <i>Endocrinology</i> 137, 331-339 (1997).	
	AY	Harada et al. Characterization of the Osteogenic Protein-1 Response Element in the Type X Collagen Promoter. <i>Mol. Biol. Cell</i> 6, Suppl. 393a: Abstract No. 2284 (1995).	
	AZ	Harada et al. Characterization of the Osteogenic Protein-1 Response Region in the Type X Collagen Promoter. <i>Bone</i> 17, 590: Abstract No. 124 (1995).	
	BA	Harada et al. Identification of an Al-1 Like Response Region for Osteogenic Protein-1 in Type X Collagen Promoter. Abstract Distributed at N.Y. Academy of Sciences, Molecular and Developmental Biology of Cartilage (September 27-30, 1995).	
	BB	Harada et al. Induction of Vascular Endothelial Growth Factor by Osteogenic Protein 1 in vitro and in vivo. <i>Am. Soc. Bone & Min Res.</i> 10, Suppl. 1: Abstract No. T268 (1995).	
	BC	Harada et al. Osteogenic Protein 1 Stimulates Type X Collagen Promoter Via a Fos Family Protein. <i>Am. Soc. Bone & Min. Res.</i> 10, Suppl. 1: Abstract No. T345 (1995).	
	BD	Harada et al. Osteogenic Protein-1 Up-Regulation of the Mouse Collagen X Promoter Activity is Mediated by a MEF-2 Like Sequence and Requires an Adjacent AP-1 Sequence. <i>Mol. Endocrinol.</i> 11, 1832-1845 (Nov. 1997).	
	BE	Harris et al. Recombinant Bone Morphogenetic Protein 2 Accelerates Bone Cell Differentiation and Stimulates BMP-2 mRNA Expression and BMP-2 Promoter Activity in Primary Fetal Rat Calvarial Osteoblast Cultures. <i>Mol. & Cell. Differentiation</i> 3, 137-155 (1995).	
	BF	Katagiri et al. Bone Morphogenetic Protein-2 Converts the Differentiation Pathway of C2C12 Myoblasts into the Osteoblast Lineage. <i>J. Cell Biol.</i> 127, 1755-1766 (1994).	
	BG	Knutsen et al. Osteogenic Protein-1 Stimulates Proliferation and Differentiation of Human Bone Cells in Vitro. <i>Biochem. & Biophys. Res. Comm.</i> 194, 1352-1358 (1993).	
	BH	Knutsen et al. Regulation of Insulin-like Growth Factor System Components by Osteogenic Protein-1 in Human Bone Cells. <i>Endocrinology</i> 136, 857-865 (1995).	
	BI	Lagna et al. Partnership between DPC4 and SMAD proteins in TGF- β signaling pathways. <i>Nature</i> 383, 832-836 (1996).	

COPY OF PAPERS
ORIGINALLY FILED

Form PTO/SB/08		Docket Number (Optional)		Application Number	
INFORMATION DISCLOSURE CITATION		CIBT-P02-540		09/613,177	
(Use several sheets if necessary)		Applicant			
		Sampath et al.			
		Filing Date		Group Art Unit	
		July 10, 2000		1655	
Lee et al. Purified Transcription Factor AP-1 Interacts with TPA-Inducible Enhancer Elements. <i>Cell</i> 49, 741-752 (1987).					
BJ					
BK	Liu et al. Simultaneous Detection of Multiple Bone-Related mRNAs and Protein Expression During Osteoblast Differentiation: Polymerase Chain Reaction and Immunocytochemical Studies at the Single Cell Level. <i>Dev. Biol.</i> 166, 220-234 (1994).				
BL	LuValle et al. Multiple Negative Elements in a Gene that Codes for an Extracellular Matrix Protein Collagen X, Restrict Expression to Hypertrophic Chondrocytes. <i>J. Cell Biol.</i> 5, 1173-1179 (1993).				
BM	Maliakal et al. Osteogenic Protein-1 (BMP-7) Inhibits Cell Proliferation and Stimulates the Expression of Marker Characteristic of Osteoblast Phenotype in Rat Osteosarcoma (17/2.8) Cells. <i>Growth Factors</i> 11, 227-234 (1994).				
BN	Massague, J. TGF β Signaling: Receptors, Transducers, and Mad Proteins. <i>Cell</i> 85, 947-950 (1996).				
BO	Merriman et al. The tissue specific nuclear matrix protein NMP-2 is a member of the AML/CBF/PEBP2/ runt domain transcription factor family: interactions with the osteocalcin gene promoter. <i>Biochem.</i> 34, 13125-13132 (1995).				
BP	Michiels et al. Retroviruses and Oncogenes Associated with Osteosarcomas. <i>Osteosarcoma in Adolescents and Young Adults</i> . G. Bennett Humphrey, ed. Kluwer Academic Publishers, Boston, MA (1993).				
BQ	Ohta et al. Bone Morphogenetic Proteins (BMP-2 and BMP-3) Induce the Late Phase Expression of the Proto-Oncogene c-fos in Murine Osteoblastic MC3T3-E1 Cells. <i>FEBS Letters</i> 314, 356-360 (1992).				
BR	Orkin et al. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy. (7 December 1995).				
BS	Rosen et al. Responsiveness of Clonal Limb Bud Cell Lines to Bone Morphogenetic Protein 2 Reveals a Sequential Relationship Between Cartilage and Bone Cell Phenotypes. <i>J. Bone & Min. Res.</i> 9, 1759-1768 (1994).				
BT	Rossert, J. A. et al. Identification of a minimal sequence of the mouse pro-alpha 1(I) collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. <i>PNAS</i> 93, 1027-1031 (1996).				
BU	Sassone-Corsi. Signaling Pathways and c-fos Transcriptional Response - Links to Inherited Diseases. <i>N.E. J. Med.</i> 322, 1576-1577 (1995).				
BV	Satoh et al. Effect of Drugs on Gene Expression in Mammalian Cells: A Highly Efficient Procedure to Test Large Numbers of Samples. <i>Nucl. Acids Res.</i> 21, 4429-4430 (1993).				
BW	Solursh, M. et al. Osteogenic Protein-1 is Required for Mammalian Eye Development. <i>Biochem. Biophys. Res. Comm.</i> 218, 438-443 (1996).				
BX	Strong et al. The Effects of the Insulin-Like Growth Factors and Transforming Growth Factor β on the Juv Proto-Oncogene Family in MC3T3-E1 Cells. <i>Calcif. Tissue Int.</i> 55, 311-315 (1994).				
BY	Thomas et al. Sequence Comparison of Three Mammalian Type-X Collagen Promoters and Preliminary Functional Analysis of the Human Promoter. <i>Gene</i> 2, 291-296 (28 July 1995).				
BZ	Topping et al. Bone Morphogenetic Proteins Increase Type X Collagen Synthesis in vivo. <i>J. Cell Biochem.</i> Abstract No. 17E: 166 (1993).				

COPY OF PAPERS
ORIGINALLY FILED

Form PTO/SB/08		Docket Number (Optional)		Application Number	
INFORMATION DISCLOSURE CITATION		CIBT-P02-540		09/613,177	
IN AN APPLICATION		Applicant			
(Use several sheets if necessary)		Sampath et al.			
		Filing Date		Group Art Unit	
		July 10, 2000		1655	
		Vainio et al. Identification of BMP-4 as a Signal Mediating Secondary Induction Between Epithelial and Mesenchymal Tissues During Early Tooth Development. <i>Cell</i> 75, 45-58 (1993).			
CB		Wang et al. Bone and Haematopoietic Defects in Mice Lacking c-fos. <i>Nature</i> 360, 741-745 (1992).			
CC		Yoon et al. Characterization of the Rat Osteocalcin Gene: Stimulation of Promoter Activity by 1, 25-Dihydroxyvitamin D ₃ . <i>Biochemistry</i> 27, 8521-8526 (1988).			
CD		Yu et al. Human Myocyte-Specific Enhancer Factor 2 Comprises a Group of Tissue-Restricted MADS Box Transcription Factors. <i>Genes & Devel.</i> 6, 1783-1798 (1992).			
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED

AUG 09 2002

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER